pipette
ESEspañol

A multi-center, single-arm, phase 2 trial of dasatinib in T follicular helper cell lymphomas

Sakurako Suma, Mamiko Sakata‐Yanagimoto, Yasuhito Suehara, Takahide Ara, Hideki Goto, Kensuke Usuki, Koji Izutsu, Motoko Yamaguchi, Noriko Fukuhara, Emiko Sakaida, Ken Ohmachi, Atsushi Uehara, Kosei Matsue, Satoshi Kimura, Hirokazu Nagai, Dai Maruyama, Mitsutaka Nishimoto, Kengo Takeuchi, Naoya Nakamura, Takashi Terauchi, Manabu Fujisawa, Yoshiaki Abe, Kenichi Makishima, Keiichiro Hattori, Tatsuhiro Sakamoto, Naoki Kurita, Hidekazu Nishikii, Futoshi Yoshino, Kenichi Yoshida, Yuko Hashimoto, Tomohiro Kaneta, Seishi Ogawa, Naoto Keino, Masahiko Gosho, Hiroyuki Hosokawa, Christian Steidl, Koichi Hashimoto, Shigeru Chiba

Peer-reviewed journalReal-world use

In the authors' words

T follicular helper cell lymphomas (TFHL) harbor activating T cell receptor (TCR) signaling mutations and epigenetic alterations, such as TET2 mutations. Here, we conduct a multi-center, single-arm, phase 2 trial of the tyrosine kinase inhibitor dasatinib in patients with relapsed/refractory TFHLs (jRCT2031190079). The primary outcome is the overall response rate (ORR) according to CT-based Lugano criteria 2014. Key secondary endpoints include ORR in RHOA-mutated patients and progression-free/overall survival. The main inclusion criteria consist of TFHL diagnosis and relapse following at least 1 prior chemotherapy regimen. Key exclusion criteria encompass central nervous system involvement, history of other malignancies, and receipt of chemotherapy or radiotherapy within 4 weeks. Nineteen patients are enrolled, with 18 receiving dasatinib and 17 evaluable for efficacy. Median age is 73 years, 50% are female, and angioimmunoblastic T cell lymphoma is the predominant subtype (n = 13). Dasatinib yields a 23.5% ORR, below the prespecified 30% endpoint. Treatment-related adverse events occur in 61.1% of patients (n = 11). Patients harboring TCR signaling mutations, especially those with RHOA p.G17V, achieve a 36.4% ORR, whereas no responses are observed in mutation-negative cases. Exploratory single-cell RNA sequencing reveals interferon-γ/tumor necrosis factor-enriched tumor microenvironments and peripheral expansion of cytotoxic T cell clones in responders. Conversely, early progression correlates with a high TET2 mutation burden in non-malignant immune cells, including CD8+ T cell subsets. While the primary outcome is below the prespecified endpoint, our exploratory findings implicate immune dysfunction involving TET2 mutations in limiting the therapeutic benefit of dasatinib. T follicular helper cell lymphomas (TFHL) depend on T cell receptor (TCR) signaling propagated by tyrosine kinases. Here, the authors conduct a phase 2 clinical trial of the tyrosine kinase inhibitor dasatinib in TFHL, not meeting the prespecified primary endpoint (ORR = 23.5%), but correlating response with TCR signaling mutations.

Main resultLimitation the authors admit

Appeared: Wednesday, October 7. Nature Communications. Peer-reviewed journal.

DOI: 10.1038/s41467-026-78100-z